Session Type
Meeting
Search Results for Alcohol
Abstract Number: 131
SHM Converge 2023
Background: Management of heart failure (HF) patients revolves around optimization of guideline directed medical therapy (GDMT) and routine monitoring. Substance use plays a major role as the etiology of HF, especially in a low socioeconomic area with ethnic and racial minority patients. The aim of this study is to find the correlation of alcohol, tobacco […]
Abstract Number: 135
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Acute alcohol withdrawal syndrome (AWS) is a common complication in hospitalized patients, but its occurrence and severity is difficult to predict based on clinical indicators alone. Phosphatidylethanol (PEth) is an abnormal phospholipid incorporated into erythrocyte lipid bilayers in proportion to levels of alcohol exposure, with a half-life of 5 to 10 days. We sought […]
Abstract Number: 138
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Treating alcohol withdrawal in the inpatient medical setting requires timely identification of the severity of alcohol withdrawal so appropriate treatment can be administered. Delayed or missed diagnosis can lead to increased morbidity and mortality, increased cost and length of stay, and ICU admissions. CIWA-Ar is the most commonly used scale, but it is lengthy […]
Abstract Number: 145
SHM Converge 2024
Background: Alcohol use disorder (AUD) Is present in 10% of adults and its prevalence is increasing. When patients with AUD are admitted to the hospital, half develop alcohol withdrawal syndrome (AWS), which can cause delirium, hallucinations, seizures, and even mortality if not treated appropriately. A fixed-dose phenobarbital strategy may be superior to the standard of […]
Abstract Number: 156
SHM Converge 2023
Background: Although alcohol withdrawal (AW) is common in hospitalized patients, few studies describe contemporary alcohol withdrawal management in hospitalized settings or compare practices to recent guidelines published by the American Society of Addiction Medicine (ASAM). We sought to describe patient characteristics and determine factors associated with complicated withdrawal and treatment duration in hospitalized patients with […]
Abstract Number: 173
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Approximately 1.6 million men and 800,000 women in the US are alcohol dependent and have an alcohol-use disorder. Half will experience withdrawal symptoms after decreased alcohol consumption. Complications including seizures and delirium tremens occur in 3-5% . Benzodiazepines are the gold standard for treatment of alcohol withdrawal but choice of drug regimens varies widely. […]
Abstract Number: 211
Hospital Medicine 2020, Virtual Competition
Background: Up to 12% of hospitalized patients require high dose parenteral thiamine treatment to prevent Wernicke’s Encephalopathy, a devastating and easily preventable neurologic disorder that can lead to death. Despite the fact that it is as simple and relatively inexpensive therapy with no known side effects, high dose thiamine continues to be underutilized. Attempts to […]
Abstract Number: 226
SHM Converge 2024
Background: Alcohol use disorder (AUD) is a pervasive disease affecting 28.6 million (11.3%) American adults in 2021.1 Medications for AUD (MAUD), including naltrexone, acamprosate, and disulfiram, are effective, yet less than 5% of these patients received treatment.1,2 Inpatient encounters of patients with AUD present a crucial opportunity to initiate MAUD, prompting this quality improvement […]
Abstract Number: 240
Hospital Medicine 2020, Virtual Competition
Background: Severe alcohol withdrawal and delirium tremens (DTs) are challenging therapeutic dilemmas. To prevent complications and death, management requires close monitoring and intensive treatment, frequently in an ICU. Benzodiazepines are first line therapeutic agents, but optimal use and dosing has been limited, due to a lack of randomized double-blind trials. In lower acuity patients admitted […]
Abstract Number: 243
SHM Converge 2023
Background: Phenobarbital (PB) has important pharmacological advantages over benzodiazepines (BZDs) for treatment of alcohol withdrawal syndrome (AWS). The American Society of Addiction Medicine recommends PB monotherapy as an alternative to BZDs for prophylaxis or treatment of AWS by providers experienced with its use. Few studies have described the use of PB for AWS outside of […]